SpringerLink
Log in

Acylcarnitines in fibroblasts of patients with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and other fatty acid oxidation disorders

  • Published:
Journal of Inherited Metabolic Disease

Abstract

Mitochondrial fatty acid oxidation disorders cause hypoglycaemia, hepatic dysfunction, myopathy, cardiomyopathy and encephalopathy. Despite their recognition for more than 15 years, diagnosis and treatment remain difficult. To help design rational diagnostic and therapeutic strategies, we studied the pathophysiology of accumulating metabolites in a whole-cell system. Acylcarnitines were quantified in cells and media of cultured fibroblasts after incubation with L-carnitine and fatty acids. Following incubation with palmitate, long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD)-deficient fibroblasts compared with controls showed elevation of hydroxypalmitoyl- and palmitoylcarnitine and reduction of C10- and shorter acylcarnitines, and following incubation with linoleate an increase in C14:2-, C18:2- and hydroxy-C18:2-acylcarnitines and reduction in C10:1-acylcarnitines. Hydroxyacylcarnitines remained more intracellular compared to corresponding saturated acylcarnitines. Incubation with decanoate and octanoate showed absence of hydroxylated acylcarnitines and correction of secondary metabolic disturbances, suggesting that optimal treatment should include medium-chain triglycerides of these chain lengths. Fibroblasts of patients with other fatty acid oxidation disorders showed distinct elevations of disease-specific acylcarnitines. This acylcarnitine analysis allows the diagnosis of LCHAD deficiency and its differentiation from other fatty acid oxidation disorders, which can pose difficulties in vivo. The strategy has allowed in-depth analysis with different substrates, providing suggestions for the rational design of treatment trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Thailand)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  • Bohmer T, Behmer J (1958) Propionylcarnitine, physiological variations in vivo. Biochim Biophys Acta 152: 559-567.

    Google Scholar 

  • Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Anal Biochem 72: 248-254.

    Google Scholar 

  • Carpenter K, Middleton B, Pollitt R (1992a) Purification of long-chain 3-hydroxyacyl-CoA dehydrogenase from human infant liver. In Coates PM, Tanaka K, eds. Progress in Clinical and Biological Research, 375: New Developments in Fatty Acid Oxidation. New York: Wiley-Liss, 75-84.

    Google Scholar 

  • Carpenter K, Pollitt RJ, Middleton B (1992b) Human liver long-chain 3-hydroxyacylcoenzyme A dehydrogenase is a multifunctional membrane-bound beta-oxidation enzyme of mitochondria. Biochem Biophys Res Commun 183: 443-448.

    Google Scholar 

  • Costa CG, Dorland L, Holwerda U, et al (1998) Simultaneous analysis of plasma free fatty acids and their 3-hydroxy analogs in fatty acid β-oxidation disorders. Clin Chem 44: 463-471.

    Google Scholar 

  • Duran M, Wanders RJA, deJager JP, et al (1991) 3-Hydroxydicarboxylic aciduria due to long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deffciency associated with sudden neonatal death: protective effect of medium-chain triglyceride treatment. Eur J Pediatr 150: 190-195.

    Google Scholar 

  • Eaton S, Bartlett K, Pourfarzam M (1996) Mammalian mitochondrial β-oxidation. Biochem J 320: 345-357.

    Google Scholar 

  • El-Fakhri M, Middleton B (1982) The existence of an inner-membrane-bound, long acylchain-specific 3-hydroxyacyl-CoA dehydrogenase in mammalian mitochondria. Biochim Biophys Acta 713: 270-279.

    Google Scholar 

  • Gillingham M, Van Calcar S, Ney D, Wol. J, Harding C (1999) Dietary management of long-chain 3-hydroxyacyl-CoA dehydrogenase deffciency (LCHADD). A case report and survey. J Inher Metab Dis 22: 123-131.

    Google Scholar 

  • Hagenfeldt L, von Dobeln U, Holme E, et al (1990) 3-Hydroxydicarboxylic aciduria-a fatty acid oxidation defect with severe prognosis. J Pediatr 116: 387-392.

    Google Scholar 

  • He X-Y, Yang S-Y, Schulz H (1992) Inhibition of enoyl-CoA hydratase by long-chain L-3-hydroxyacyl-CoA and its possible effect on fatty acid oxidation. Arch Biochem Biophys 298: 527-531.

    Google Scholar 

  • Ijlst L, Ruiter JPN, Hoovers JMN, Jakobs ME, Wanders RJA (1996) Common missense mutation G1528C in long-chain 3-hydroxyacyl-CoA dehydrogenase deffciency. J Clin Invest 98: 1028-1033.

    Google Scholar 

  • Kler RS, Jackson S, Bartlett K, et al (1991) Quantitation of acyl-coA and acylcarnitine esters accumulated during abnormal mitochondrial fatty acid oxidation. J Biol Chem 266: 22932-22938.

    Google Scholar 

  • Kobayashi A, Jiang LL, Hashimoto T (1996) Two mitochondrial 3-hydroxyacyl-CoA dehydrogenase in bovine liver. J Biochem 119: 775-782.

    Google Scholar 

  • Libert R, Van Hoof F, Thillaye M, et al (1997) Identification of new medium-chain acylcarnitines present in normal human urine. Anal Biochem 251: 196-205.

    Google Scholar 

  • Luo MJ, He X-Y, Sprecher H, Schulz H (1993) Purification and characterization of the trifunctional β-oxidation complex from pig heart mitochondria. Arch Biochem Biophys 304: 266-271.

    Google Scholar 

  • Millington DS, Chace DH (1992) Carnitine and acylcarnitines in metabolic disease diagnosis and management. In Desiderio DM, ed. Mass Spectrometry: Clinical and Biomedical Applications, Vol. I. New York: Plenum Press, 299-318.

    Google Scholar 

  • Millington DS, Norwood DL, Kodo N, Roe CR, Inuoe F (1989) Application of fast atom bombardment with tandem mass spectrometry and liquid chromatography/mass spectrometry to the analysis of acylcarnitines in human urine, blood, and tissue. Anal Biochem 180: 331-339.

    Google Scholar 

  • Morris AAM, Shortland GJ, van Wijk K, et al (1998) Use of medium-chain triglyceride in long-chain 3-hydroxyacyl-CoA dehydrogenase deffciency. J Inher Metab Dis 21(supplement 3): 3 (Abstract).

    Google Scholar 

  • Nada MA, Chace DH, Sprecher H, Roe CR (1995a) Investigation of β-oxidation in normal and MCAD-deficient human fibroblasts using tandem mass spectrometry. Biochem Mol Med 54: 59-66.

    Google Scholar 

  • Nada MA, Rhead WJ, Sprecher H, Schulz H, Roe CR (1995b) Evidence for intermediate channeling in mitochondrial β-oxidation. J Biol Chem 270: 530-535.

    Google Scholar 

  • Pons R, Roig M, Riudor E, et al (1996) The clinical spectrum of long-chain 3-hydroxyacyl-CoA dehydrogenase deffciency. Pediatr Neurol 14: 236-243.

    Google Scholar 

  • Pourfarzam M, Schaefer J, Turnbull DM, Bartlett K (1994) Analysis of fatty acid oxidation intermediates in cultured fibroblasts to detect mitochondrial oxidation disorders. Clin Chem 40: 2267-2275.

    Google Scholar 

  • Roe CR, Coates PM (1995) Mitochondrial fatty acid oxidation disorders. In Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 7th edn. New York: McGraw-Hill, 1501-1533.

    Google Scholar 

  • Schaefer J, Pourfarzam M, Bartlett K, Jackson S, Turnbull DM (1995) Fatty acid oxidation in peripheral blood cells: characterization and use for the diagnosis of defects of fatty acid oxidation. Pediatr Res 37: 354-360.

    Google Scholar 

  • Thorpe C (1990) The reductive half reaction in the acyl-CoA dehydrogenases. In Tanaka K, Coates P, eds. Progress in Clinical and Biological Research, 321 Fatty Acid Oxidation: Clinical, Biochemical, and Molecular Aspects. New York: Alan R. Liss, 91-105.

    Google Scholar 

  • Treem WR, Shoup ME, Hale DE, et al (1996) Acute fatty liver of pregnancy, hemolysis, elevated liver enzymes, and low platelets syndrome, and long chain 3-hydroxyacylcoenzyme A dehydrogenase deffciency. Am J Gastroenterol 91: 2293-2300.

    Google Scholar 

  • Tyni T, Paloti A, Vlinikka L, et al (1997) Long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deffciency with the G1528C mutation: clinical presentation of thirteen patients. J Pediatr 130: 67-76.

    Google Scholar 

  • Uchida Y, Izai K, Orii T, Hashimoto T (1992) Novel fatty acid b-oxidation enzymes in rat liver mitochondria. II. Purification and properties of enoyl-coenzyme A (CoA) hydratase/3-hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase trifunctional protein. J Biol Chem 267: 1034-1041.

    Google Scholar 

  • Van Hove JLK, Kahler SG, Ramakrishna JP, et al (1997) Acylcarnitines in 3-hydroxy-longchain-acyl-CoA dehydrogenase deficiency. Paper presented at the 7th International Congress of Inborn Errors of Metabolism, Vienna, Austria.

  • Ventura FV, Ijlst L, Ruiter J, et al (1998) Carnitine palmitoyltransferase II specificity towards β-oxidation intermediates. Evidence for a reverse carnitine cycle in mitochondria. Eur J Biochem 253: 614-618.

    Google Scholar 

  • Verhoeven NM, Roe DS, Kok RM, Wanders RJA, Jakobs C, Roe CR (1998) Phytanic and pristanic acid are oxidized by sequential peroxisomal and mitochondrial reactions in cultured fibroblasts. J L ipid Res 39: 66-74.

    Google Scholar 

  • Vianey-Saban C, Divry P, Brivet M, et al (1998) Mitochondrial very-long chain acylcoenzyme A dehydrogenase deficiency: clinical characteristics and diagnostic considerations in 30 patients. Clin Chim Acta 269: 43-62.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, USA

    J. J. Shen, D. Matern, D. S. Millington, S. Hillman, M. D. Feezor, S. G. Kahler, Y.-T. Chen & J. L. K. Van Hove

  2. Departments of Pathology and Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA

    M. J. Bennett

  3. Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA

    M. Qumsiyeh

  4. The Victorian Clinical Genetics Services, The Murdoch Institute, Parkville, Melbourne, Victoria, Australia

    S. G. Kahler

  5. Department of Pediatrics, Katholieke Universiteit Leuven, Leuven, Belgium

    J. L. K. Van Hove

Authors
  1. J. J. Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Matern
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. S. Millington
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Hillman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. D. Feezor
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. J. Bennett
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Qumsiyeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S. G. Kahler
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Y.-T. Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J. L. K. Van Hove
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shen, J.J., Matern, D., Millington, D.S. et al. Acylcarnitines in fibroblasts of patients with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and other fatty acid oxidation disorders. J Inherit Metab Dis 23, 27–44 (2000). https://doi.org/10.1023/A:1005694712583

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005694712583

Keywords

Search

Navigation